Journal of Diabetes & Metabolism

ISSN - 2155-6156

+441518081309

Research Article - (2013) Volume 4, Issue 4

Glycemic Control of Patients with Type 1 Diabetes Mellitus in Saudi Community

Khalid S. Aljabri* and Samia A. Bokhari
Division of Endocrinology, Department of Internal Medicine, King Fahad Armed Forces Hospital, Saudi Arabia
*Corresponding Author: Khalid S. Aljabri, Division of Endocrinology, Department of Internal Medicine, King Fahad Armed Forces Hospital, Jeddah, PO Box 6572, Makkah, Kingdom of Saudi Arabia, Tel: 966590008035, Fax: 966(02)5760665 Email:

Abstract

Background and objective: The incidence of type 1 diabetes is increasing; Blood glucose may be the most important clinical characteristic of diabetic patients. Few studies have measured glycemic control in a representative national sample of people with diabetes The aim of this study were to describe glycemic control in patients with type 1 diabetes Mellitus.

Methods: A cross section study of patients with type 1 diabetes mellitus at the diabetic centre in Saudi Arabia

Main results: There were 220 patients with type 1 diabetes mellitus, 91 male (41.4%) and 129 female (58.6%). The mean age was 21.3 ± 7.2. The mean diabetes duration was 7.5 ± 5.7. Male patients were not significantly different in age, diabetes duration, body mass index and HbA1c than female patients. The correlation of HbA1c and age, diabetes duration and body mass index were (-0.2, p<0.0001), (-0.2, p=0.001) and (-0.01, p=0.2) respectively. Younger patients (<20 years old) were significantly had higher mean HbA1c than older patients (≥ 20 years old), 9.9 ± 2.3 and 8.9 ± 2.2 respectively (1.0, 95% CI; 0.4, 1.6), p=0.001. Patients with diabetes duration more than 10 years were significantly had lower mean HbA1c than patients with diabetes duration between 5 and 10 years and less than 5 years; 10.1 ± 2.7 , 9.2 ± 2.0 and 8.9 ± 1.9 respectively, p=0.004.

Conclusion: Many patients with type 1 diabetes have poor glycemic control placing them at high risk of diabetic complications.

Keywords: Type 1 diabetes mellitus; Glycemic control; HbA1c

Introduction

Type 1 diabetes mellitus (T1DM) results from a cellular-mediated autoimmune destruction of the β-cells of the pancreas [1]. T1DM accounts for about 10% of all diabetes, affecting approximately 1.4 million people in the U.S., and 10-20 million globally [2]. The prevalence of T1DM was 0.193% in the Saudi males and 0.237% in the Saudi females [3]. Blood glucose may be the most important clinical characteristic of diabetic patients. Not only does the level of blood glucose define the disease [1], it is a major risk factor for complications of diabetes. Control of hyperglycemia can reduce the incidence of acute diabetic complications and long-term end-stage macrovascular and microvascular complications in T1DM [4]. Despite the clear importance of hyperglycemia, few studies have measured glycemic control in a representative national sample of people with T1DM [5]. Therefore, we describe the glycemic control of population with T1DM in our institution.

Methods

Eligible patients were older than 12 years old, had T1DM [1]. All patients were recruited from the population of the Diabetic Centre at King Fahad Armed Forces Hospital between January 2008 and June 2009. All the patients gave their or their guardian informed consent prior to their inclusion. The study was approved by the ethical board of King Fahad Armed Forces Hospital. Eligible patients met with investigators for a complete history and physical examination, to have baseline laboratory assessments including glycosylated hemglobin (HbA1c). HbA1c was expressed as percentage and measured using the high performance liquid chromatography.

Statistical analysis

Univariate analysis of baseline and follow up demography and clinical laboratory endpoints were accomplished using unpaired t-test where appropriate. Chi square (χ2) test were used for categorical data comparison. Pearson’s correlations between continuous variables were used as a measure of association. The data were analyzed by one-way analysis of variance (ANOVA), to estimate the significance of different between groups. All statistical analyses were performed using SPSS Version 16.0. All P values were based on two-sided tests. The difference between groups was considered significant when P<0.05.

Results

Two hundred twenty patients completed the study. Baseline characteristics are shown in table 1. There were no significant differences in mean HbA1c between male and female groups, (-0.04, 95% CI; -0.7, 0.6), P=0.9. The correlation of HbA1c with age, diabetes duration and body mass index were (-0.2, p<0.0001), (-0.2, p=0.001) and (0.01, p=0.2) respectively. The correlation of HbA1c with diabetes duration for male were (-0.4, p=0.001), and for female with age were (-0.3, p=0.003).

Parameters Total Male Female P value
n (%) 220 91 (41.4) 129 (58.6)  
Age (years) 21.3 ± 7.2 21.1 ± 7.0 21.4 ± 7.4 0.8
Age at diagnosis of diabetes(years) 13.8 ± 7.2 14.1 ± 6.8 13.6 ± 7.5 0.6
Age groups (years) <20 109 (49.5) 45 (49.5) 64 (49.6) 1.0
≥ 20 111 (50.5) 47 (50.5) 65 (50.4)
Duration of diabetes (years) 7.5 ± 5.7 7.0 ± 5.4 7.8 ± 6.0 0.3
Body mass index (kg/m2) 18.8 ± 4.6 19.0 ± 5.4 18.7 ± 3.9 0.7
HbA1c 9.4 ± 2.3 9.4 ± 2.2 9.5 ± 2.4 0.9
Data are means ± SD or number (%)

Table 1: Characteristics of patients with type 1 diabetes mellitus stratified by gender.

HbA1c<7.0 were achieved in 9.5%, 7.7 and 10.9 were male and female respectively, p=0.4. There were significant differences in achieved HbA1c<7.0 between the groups who are younger or older than 20 years; 3.7% and 15.3% respectively, P=0.003. There were significant differences in achieved HbA1c<7.0 between the female who are younger or older than 20 years; 4.7% and 16.9% respectively, P=0.03. There were significant differences in the tertiles of HbA1c between the gender groups and within the age groups of female patients (Table 2) (Figure 1). There were significant differences in the diabetes duration between the gender groups and within the age groups of male patients (Table 3).

Parameters Male Female
Age (years) <20 ≥ 20 Total Total <20 ≥ 20
HbA1c <8 17.8 30.4 20.2 39.6 21.9 46.2
8-10 48.9 41.3 40.4 37.8 34.4 35.4
>10 33.3 28.3 39.4 22.5 43.8 18.5
P value 0.4 0.002 0.002
Data are in percentage

Table 2: Characteristics of patients with type 1 diabetes mellitus stratified by HbA1c to gender and age.

diabetes-metabolism-Mean-HbA1c

Figure 1: Mean HbA1c levels in gender groups and age groups.

Diabetes duration (years) <5 5-10 >10 P value
Male 10.4 ± 2.5 8.9 ± 1.6 8.5 ± 1.8 0.001
Female 9.8 ± 2.9 9.4 ± 2.2 9.1 ± 2.0 0.6
Total 10.1 ± 2.7 9.2 ± 2.0 8.9 ± 1.9 0.004

Table 3: Mean HbA1c of patients with type 1 diabetes mellitus stratified by diabetes duration to gender.

Discussion

This study makes several contributions to clinical studies of glycemic control in patients with T1DM. Due to regionalized characteristics, thus, our data cannot be generalized to the overall population. Moreover, it does not represent the general conditions of healthcare services offered in our city. Other aspect that should be considered in the assessment of our results is the size of our sample and the cross section type of the study.

The reductions in HbA1c levels achieved in the intensive therapy arm of the DCCT were associated with decreased rates in the appearance and progression of microvascular complications, in comparison to conventional therapy. These differences in complications persisted even though the differences in glycemic control between the two therapy arms narrowed after the trial ended. The benefits of tight glycemic control in preventing or delaying microvascular complications are therefore clear [6].

In our study, the average HbAlc of 9.4% was higher to that described in Belgium with values of 6.6%, a cross-sectional multi-centered study in Europe, Japan, and the United states, with values of 8.6% [7,8], and is similar to the only other published data: Denmark (mean HbA1c 9.1%) and a cross-sectional study with children and adolescents in France (mean HbA1c 9.0%) and a population based study in Scotland with value of 9.1 % [9-11]. The DCCT described patients with over 13 years of age who had intensive treatment and multidisciplinary team support presenting HbAlc, at the end of the study, of 7.1%. The comparison of our results with those described above allows for the conclusion that our services are not providing satisfactory glycemic control results.

90.5% were not able to achieve the American Diabetes Association goal and only 27.7% of patients had a HbA1c concentration less than 8% comparable to other studies [12]. That makes our population at risks for diabetes complications. Several factors may contribute to these observations. Many barriers to tight glycemic control exist in clinical practice that are not found in trial settings. The DCCT suggested that switching to a more intensive insulin regimen (four or more daily injections or pump therapy), even in young people with type 1 diabetes, was the major factor in producing good glycemic control [13]. Since the publication of the DCCT, tight glycemic control, with HbA1c <7%, has been one of the central aims of diabetes care. However, after the publication of the study, debate ensued, suggesting that the “clinical support package” (i.e., intensive medical follow-up, additional nursing and dietetic input, and frequent contact) was the main reason for the improvement in glycemic control [14]. Recently, further strategies have been introduced to optimize glycemic control. These include an intensive education programme; Dose Adjustment for Normal Eating (DAFNE), DAFNE may produce short-term improvements in HbA1c levels, but long-term data on sustained tight control is lacking [15]. A highly motivated patient willing to commit time and comply with advice is needed, along with considerable nurse educator resources. Many patients do not comply with regimens long-term or move away from the clinic area. Diabetic patients who frequently missed appointments had substantially poorer glycemic control than those who missed none. Pharmacologically treated patients missing more than 30% of scheduled visits had an HbA1c value 0.7 point higher relative to those with perfect attendance, a difference that is clinically relevant. Missing appointments could have a direct effect on clinical outcomes by reducing continuity of care, missing opportunities to measure clinical variables or adjust medications, delaying the appropriate timing of interventions and screenings, and hindering the development of a trusting provider–patient relationship. The number of appointments necessary per year for optimal health care and diabetes control varies greatly, and there is no recommended minimum; however, we assume that office visits are medically necessary and that a missed appointment is potentially detrimental to care management [16,17]. Appointments cannot be offered as frequently as visits in clinical trials, due to resource limitations. None of our patients were treated with continuous subcutaneous insulin infusions SII), in contrast to many patients in the intensive cohort of the DCCT. Some studies suggest that use of CSII may confer an advantage over Multiple daily injections in achieving better glycemic control others not [18-21]. CSII is more expensive than MDI administration, requires a highly motivated patient without psychological problems, and an experienced diabetes team who can provide regular and frequent input into the ongoing care of the patient. The recently introduced long-acting analogue such as insulin glargine may be useful in improving fasting hyperglycaemia and reducing the incidence of hypoglycaemic episodes in patients with type 1 diabetes [22-26]. It is possible that the use of long-acting analogues may encourage the patient to aim for tighter glycemic control, without the fear of hypoglycaemia leading to defensive reductions in insulin doses.

Different studies with T1DM children and adolescents demonstrated that 34-62% of patients maintained a satisfactory level of HbAlc with good glycemic control. Different factors associated to general population of children can cause fluctuations of glycemia and, consequently, affect HbAlc and upset the maintenance of good glycemic control [7,8,10]. The relatively high prevalence of poor glycemic control achieved in this study, reflects the greater needs for more efforts for improvement.

Conclusion

These data indicate that many patients with type 1 diabetes in our community have poor glycemic control placing them at high risk of diabetic complications. It provides important clues as to the magnitude and structure of the primary and secondary intervention programs that will be required to effectively manage this disease. More national studies are needed to assess glycemic control among diabetic patients in the Kingdom.

Acknowledgements

We are grateful to Dr. Murtadha Khan and Dr. Ahamd Al-Akl and the staffs from the diabetic centre at King Fahad Armed Forces Hospital for his valuable contributions in data collection. The authors have no conflict of interest to disclose.

References

  1. American Diabetes Association (2009) Diagnosis and Classification of Diabetes Mellitus. Definition and description of diabetes mellitus. Diabetes Care 34: S62-S69.
  2. King H, Rewers M (1993) Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group. Diabetes Care 16: 157-177.
  3. El-Hazmi MA, Warsy AS, Al-Swailem AR, Al-Swailem AM, Sulaimani R, et al. (1996) Diabetes mellitus and impaired glucose tolerance in Saudi Arabia. Ann Saudi Med 16: 381-385.
  4. The Diabetes Control and Complications Trial Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986.
  5. El-Hazmi MA, Warsy AS (1989) Comparative study of hyperglycemia in different regions of Saudi Arabia. Ann Saudi Med 21: 43-48.
  6. Barr CC (2001) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive insulin therapy, by The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N. Engl. J. Med 342:381-9, 2000. Surv Ophthalmol 45: 459-460.
  7. Dorchy H, Roggemans MP, Willems D (1997) Glycated hemoglobin and related factors in diabetic children and adolescents under 18 years of age: a Belgian experience. Diabetes Care 20: 2-6.
  8. Mortensen HB, Hougaard P (1997) Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries. The Hvidøre Study Group on Childhood Diabetes. Diabetes Care 20: 714-720.
  9. Mortensen HB, Marinelli K, Nørgaard K, Main K, Kastrup KW, et al. (1990) A nation-wide cross-sectional study of urinary albumin excretion rate, arterial blood pressure and blood glucose control in Danish children with type 1 diabetes mellitus. Danish Study Group of Diabetes in Childhood. Diabet Med 7: 887-897.
  10. Rosilio M, Cotton JB, Wieliczko MC, Gendrault B, Carel JC, et al. (1998) Factors associated with glycemic control. A cross-sectional nationwide study in 2,579 French children with type 1 diabetes. The French Pediatric Diabetes Group. Diabetes Care 21: 1146-1153.
  11. Scottish Study Group for the Care of the Young Diabetic (2001) Factors influencing glycemic control in young people with type 1 diabetes in Scotland: a population-based study (DIABAUD2). Diabetes Care 24: 239-244.
  12. Thomsett M, Shield G, Batch J, Cotterill A (1999) How well are we doing? Metabolic control in patients with diabetes. J Paediatr Child Health 35: 479-482.
  13. [No authors listed] (1994) Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr 125: 177-188.
  14. Boulton AJ (1993) DCCT: implications for diabetes care in the UK. Diabet Med 10: 687.
  15. (2002) Training in flexible, intensive insulin management to enabledietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. Br Med J 325: 746.
  16. Parchman ML, Pugh JA, Noël PH, Larme AC (2002) Continuity of care, self-management behaviors, and glucose control in patients with type 2 diabetes. Med Care 40: 137-144.
  17. Karter AJ, Parker MM, Moffet HH, Ahmed AT, Ferrara A, et al. (2004) Missed appointments and poor glycemic control: an opportunity to identify high-risk diabetic patients. Med Care 42: 110-115.
  18. Saurbrey N, Arnold-Larsen S, Møller-Jensen B, Kühl C (1988) Comparison of continuous subcutaneous insulin infusion with multiple insulin injections using the NovoPen. Diabet Med 5: 150-153.
  19. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber JP (2002) Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. Diabetes Care 23: 1232-1235.
  20. Bak JF, Nielsen OH, Pedersen O, Beck-Nielsen H (1987) Multiple insulin injections using a pen injector versus insulin pump treatment in young diabetic patients. Diabetes Res 6: 155-158.
  21. Marshall SM, Home PD, Taylor R, Alberti KG (1987) Continuous subcutaneous insulin infusion versus injection therapy: a randomized cross-over trial under usual diabetic clinic conditions. Diabet Med 4: 521-525.
  22. Bott U, Ebrahim S, Hirschberger S, Skovlund SE (2003) Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes. Diabet Med 20: 626-634.
  23. Del Sindaco P, Ciofetta M, Lalli C, Perriello G, Pampanelli S, et al. (1998) Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med 15: 592-600.
  24. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, et al. (2000) Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 23: 639-643.
  25. Wang F, Carabino JM, Vergara CM (2003) Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther 25: 1541-1577.
Citation: Aljabri KS, Bokhari SA (2013) Glycemic Control of Patients with Type 1 Diabetes Mellitus in Saudi Community. J Diabetes Metab 4:256.

Copyright: © 2013 Aljabri KS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.